Liver Disease Research Studies

Contact Information
 
University of Wisconsin GI and Hepatology Clinical Research Office:
(608) 263-4185
 
Resources
 
Learn more about clinical trials at www.clinicaltrials.gov
ACHIEVE (Hepatitis C Virus - HCV)
Principal Investigator (PI): Michael Lucey, MD
Target Enrollment: 6 patients
 
Phase III, randomized study evaluating efficacy and safety of albumin interferon alfa 2b (alb-IFN) with ribavirin compared with peginterferon alfa-2a (PEGASYS or PEG-IFNa2a) with ribavirin.
  • Genotype 1, IFNa treatment naive

Exclusions:

  • Decompensated liver disease including ascites, bleeding varices or hepatic encephalopathy
  • History of psychiatric disease, especially depression
  • Positive for HIV-1 or hepatitis B surface antigen (HBsAG)
  • Clinical diagnosis of other causes of chronic liver disease including but not limited to hepatitis B, autoimmune hepatitis, primary biliary cirrhosis, alcoholic liver disease, hemocromatosis, Wilson's Disease or alpha 1-antitrypsin deficiency
  • All HCV patients who are treatment-naive should be considered for this study

 

AGA (Hepatitis C Virus - HCV)
Principal Investigator (PI): Adnan Said, MD

Enrollment Target: 160 patients

 

Evaluating whether or not HCV-related liver disease advances faster in those who drink no alcohol vs. those who drink moderate amounts of alcohol.

  • Not currently being treated for HCV (non-responders and relapsers are allowed)
  • Abstinent from alcohol or drinking no more than 2 drinks/day
  • Liver biopsy within 2 years
  • All HCV patients who are not currently being treated should be considered for this study

 

PROTECT (HCV Treatment Post-Liver Transplant)

Principal Investigator (PI): Michael Lucey, MD

Enrollment Target: 5 patients

 

Evaluating efficacy and safety of Peg-Intron/Riba in current HCV.

  • 3 months to 3 years post-liver transplant
  • 48 weeks of treatment regardless of genotype
  • No other cause of liver disease (concomitant alcoholic liver disease acceptable)
  • Subjects must be on stable doses of immunosuppression for at least one month
Salix (Liver Disease)
Principal Investigator (PI): Michael Lucey, MD
Enrollment Target: 5 patients
 
Evaluating Rifaximin in the treatment of hepatic encephalopathy.
  • At least 2 episodes of HE (hepatic encephalopathy) within the past 6 months, but not currently having symptoms
  • Close personal contact (friend or relative) who can provide oversight during the trial
  • There are a number of exclusionary medications for this study, but the coordinators will talk to any potential patients and determine eligibility
 
Contact Information

If you are a patient interested in learning more about our clinical studies, or if you are a referring physician and believe one of your patients may be appropriate for one of these trials, please call the University of Wisconsin GI and Hepatology Clinical Research Office at (608) 263-4185.